Zimmer Biomet Holdings, Inc. ZBH

I advise new and inexperienced traders who are looking for a way to invest and make money while still being unable to profit from stocks, I know of one financial industry specialist who can help an insured accurate prediction availability connect with Laura Ben Wesley via her ????????+1(541)310-7087

Coiling…

Setting up to run here?

$OCGN

How many knew that Ocugen had a partnership which contractually GUARANTEES them revenues from Covid19 Antibody Testing?

(re: page 22 of annual report):

https://www.sec.gov/Archives/edgar/data/1372299/000110465920053502/tm2017927-1_10ka.htm
Collaboration with Advaite, Inc.
 In April 2020, the Company entered into an agreement with Advaite, Inc., (Advaite) to provide certain support services for Advaite's development of a diagnostic test kit that is designed to detect antibodies to COVID-19. ...{Ocugen}... will receive tiered royalty payments based on cumulative net sales of the test kit.

The projected market for Covid diagnostic testing is $61B AND GROWING!

https://www.globenewswire.com/news-release/2020/05/28/2040176/0/en/61-Billion-In-Vitro-Diagnostics-IVD-Market-Assessment-2020-Implications-of-COVID-19-till-2025.html

MORE IMPORTANTLY Advaite is NOW MOVING on Covid Antibody Testing!

https://www.linkedin.com/mwlite/company/advaite
*

The BEAUTY here:
NOBODY KNOWS Ocugen will be collecting potentially BILLION$ in COVID DIAGNOSTICS revenue! They NEVER did a PRESS RELEASE!

$OBSV
Don’t mis this run. Lots of upside potential.

ObsEva SA (NASDAQ:OBSV) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA‘s (NASDAQ:OBSV) latest quarterly results. Revenues came in 113% better than analyst models expected, at US$4.0kwhile statutory losses per share were US$0.48, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

$OBSV
Don’t mis this run. Lots of upside potential.

ObsEva SA (NASDAQ:OBSV) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA‘s (NASDAQ:OBSV) latest quarterly results. Revenues came in 113% better than analyst models expected, at US$4.0kwhile statutory losses per share were US$0.48, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.